sorafenib teva 200 mg apvalkotās tabletes
teva b.v., netherlands - sorafenibs - apvalkotā tablete - 200 mg
sorafenib sandoz 200 mg apvalkotās tabletes
sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 200 mg
sorafenib zentiva 200 mg apvalkotās tabletes
zentiva, k.s., czech republic - sorafenibs - apvalkotā tablete - 200 mg
sorafenib sandoz 400 mg apvalkotās tabletes
sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 400 mg
weldinin 200 mg apvalkotās tabletes
egis pharmaceuticals plc, hungary - sorafenibs - apvalkotā tablete - 200 mg
xorafia 200 mg apvalkotās tabletes
lv system service sia, latvia - sorafenibs - apvalkotā tablete - 200 mg
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiski līdzekļi - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastiskie līdzekļi aģentu - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
poteligeo
kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastiski līdzekļi - poteligeo ir norādīts ārstēšanai pieaugušiem pacientiem ar mycosis fungoides (mf) vai sézary sindroms (ss), kuri ir saņēmuši vismaz vienu pirms sistēmiskā terapija.